Hello, welcome to the Intensity Therapeutics, Inc. annual meeting. I will now turn it over to Lewis Bender, President, Chief Executive Officer, and Chairman of the company. Please go ahead. Thank you, Sarah. Good morning, welcome to the 2026 annual meeting of stockholders of Intensity Therapeutics Incorporated. I'm Lew Bender, President, Chief Executive Officer, and Chairman of the company, it is my pleasure to welcome all of you. It is 10:30 A.M. Eastern Time, in accordance with the notice of the meeting, I call to order the 2026 annual meeting of stockholders of Intensity Therapeutics, Inc. We have chosen to have this meeting virtually in order to improve our stockholders' access to this meeting. It is our intention to conduct this meeting in accordance with the agenda. The agenda is currently available for review in the Meeting Materials section of the meeting website. You will note that under Item 10 of the agenda, an opportunity is provided at the end of the meeting for general questions and discussion. Please adhere to the rules for conduct attached to your agenda in asking questions at that time. Before proceeding to the business of the meeting, I would like to introduce some people who are with us today on the webcast. First, I would like to introduce our present directors. In addition to myself, we are welcomed by Dr. Emer Leahy, Dr. Mark Goldberg, Dan Donovan, Thomas Dubin. Dr. Emer Leahy and I are candidates for re-election at today's meeting. Also present today are Joseph Talamo, the company's Chief Financial Officer, John Wesolowski, the company's Principal Accounting Officer and Controller, as well as Jeff Schultz and Kostas Skordalos from Mintz, the company's attorneys. James R. Alden of American Election Services, LLC is here as the Inspector of Election for this meeting. If questions arise during the discussion period that these individuals should appropriately address, they will be glad to respond. Joseph Talamo will serve as Secretary of the meeting. This meeting is held pursuant to a printed notice mailed on or about April 30, 2026, to each stockholder of record on April 23, 2026. The count of shares present immediately prior to the commencement of the meeting indicated that 1,079,474 shares of the company's voting capital were present in person or by proxy. This is 40.74% of the outstanding voting stock of the company. I hereby declare a quorum present at the meeting. On behalf of the board of directors, I would like to express my appreciation to all stockholders who returned their proxies. I would also like to point out that most of you who returned proxies authorized the persons named in the proxies to vote for the election of management's nominees for director. Those of you who would like to vote today may do so by clicking on the button on your screen entitled Vote Here. The first matter to be acted upon by the stockholders is the election of two directors to serve until the annual meeting to be held in 2029 and until their respective successors have been elected and qualified. I have just introduced the nominees and any additional information about the nominees is in the proxy statement. I hereby declare Dr. Emer Leahy and Mr. Lewis Bender duly nominated. The company has not received timely notice of any other nominations, therefore, I declare the nominations closed. If you have any questions regarding this proposal, please submit questions regarding this proposal now. The next matter being submitted to stockholders for action is the ratification of the appointment by the board of directors of EisnerAmper LLP as auditors of Intensity Therapeutics, Inc. If you have questions regarding this proposal, please submit questions regarding this proposal now. The next matter being submitted to stockholders for action is the approval of an amendment to our 2021 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under our 2021 Stock Incentive Plan by 150,000 shares. If you have questions regarding this proposal, please submit questions regarding this proposal now. The next matter being submitted to stockholders for action is the approval of an amendment to our 2024 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under our 2024 Employee Stock Purchase Plan by 25,000 shares. If you have questions regarding this proposal, please submit questions regarding this proposal now. The next matter being submitted to stockholders for action is the approval of any postponement or adjournment of this 2026 annual meeting from time to time, if necessary, to solicit additional proxies if there are not sufficient votes to adopt the proposals mentioned or to establish a quorum. If you have questions regarding this proposal, please submit questions regarding this proposal now. The stockholders who are voting at this meeting on these proposals should now vote. The polls will be open for one additional minute to vote on all proposals. After voting has been completed, votes will be counted. Please vote on each proposal using the links provided in the webcast. During this pause, I will read our forward-looking statement disclosure. Please be advised that my remarks and management's responses to questions at the end of the meeting will contain some forward-looking statements. In compliance with the Private Securities Litigation Reform Act of 1995, I am advised to point out that actual results may differ significantly from results discussed in the forward-looking statements. Factors that might cause a difference include those set forth from time to time in the company's SEC filings, including its annual report on Form 10-K for the year ended 2025. At this time, I hereby declare the polls closed for all proposals. We will prepare preliminary results of the voting at this time. We have completed a preliminary count of the ballots, and a majority of the votes cast have been voted for the election of Dr. Emer Leahy and Mr. Lewis H. Bender for a term expiring in 2029. In connection with the ratification of the appointment of EisnerAmper LLP to audit the financial statements of the company and its subsidiaries for fiscal year 2026, 1,025,805 shares, being more than a majority of the votes cast, have been voted in favor, 4,839 shares have been voted against, 48,830 shares have abstained. In connection with the approval of an amendment to our 2021 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under our 2021 Stock Incentive Plan by 150,000 shares, 363,289 shares, being more than a majority of the votes cast, have been voted in favor, 68,406 shares have been voted against, 2,359 shares have abstained. In connection with the ratification of the approval of an amendment to our 2024 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under our 2024 Employee Stock Purchase Plan by 25,000 shares, 406,958 shares, being more than a majority of the votes cast, have been voted in favor, 24,696 shares have been voted against, 2,400 shares have abstained. In connection with the approval of any postponement or adjournment of this 2026 annual meeting from time to time, if necessary, to solicit additional proxies, if there were not sufficient votes to adopt the proposal set forth above to establish a quorum, 940,978 shares, being more than a majority of the votes cast, have been voted in favor, 126,006 shares have been voted against, 12,490 shares have abstained. I hereby declare that Dr. Emer Leahy and Mr. Lewis Bender have been duly elected, that the appointment of EisnerAmper LLP to audit the financial statements of the company for fiscal year 2026 has been duly ratified, that the amendment to our 2021 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under our 2021 Stock Incentive Plan by 150,000 shares has been approved, that the amendment to our 2024 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under our 2024 Employee Stock Purchase Plan by 25,000 shares has been approved, that any postponement or adjournment of this 2026 annual meeting from time to time, if necessary, to solicit additional proxies, if there were not sufficient votes to adopt the proposals mentioned or to establish a quorum, has been approved. After the final tabulation has been completed, it shall be placed in the minutes of this meeting. The final results will be disclosed in a current report on Form 8-K to be filed within four business days of the meeting. This concludes the formal portion of our meeting. I would again like to express my sincere appreciation to the stockholders who attended the meeting and voted, as well as those who submitted their proxies. The meeting is now formally adjourned. However, we are available to discuss questions which any of you may have. We have now come to the part of the agenda providing for general questions and discussion. We have not received any questions, the Q&A portion of the meeting is now closed. Thank you again to our stockholders. This concludes today's meeting. We thank you for joining. You may now disconnect.